Health knowledge made personal
Join this community!
› Share page:
Search posts:

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

Posted Jun 15 2010 5:00pm

Description of Invention:
The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.

In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.

Development Status:
In vitro and in vivo data are available.

Jacqueline A Shukaliak-Quandt (NINDS)

Patent Status:
HHS, Reference No. E-153-2005/2
US, Application No. 12/444,854 filed 25 Feb 2010

Licensing Status:
Available for non-exclusive or exclusive licensing.

Central Nervous System
Central Nervous System - Therapeutics
In-vivo Data
In-vitro Data

For Additional Information Please Contact:
Norbert Pontzer Ph.D., J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 23,
Rockville, MD 20852
United States
Phone: 301-435-5502
Fax: 301-402-0220

Ref No: 1817

Updated: 06/2010

Post a comment
Write a comment:

Related Searches